<DOC>
	<DOCNO>NCT03063489</DOCNO>
	<brief_summary>Evaluation Safety , Systemic Pharmacokinetics , Tolerability Single Repeat Ocular Instillations Loteprednol Etabonate Ophthalmic Gel , Normal Healthy Volunteers</brief_summary>
	<brief_title>Evaluation Safety , Systemic Pharmacokinetics , Tolerability</brief_title>
	<detailed_description>The primary objective study evaluate systemic pharmacokinetics ( PK ) LE ( loteprednol etabonate ophthalmic gel ) , 0.38 % normal healthy volunteer subject least 18 year age normal ophthalmic history . Systemic PK assess study single dose 2 week daily BID dosing .</detailed_description>
	<mesh_term>Eye Pain</mesh_term>
	<mesh_term>Loteprednol Etabonate</mesh_term>
	<criteria>Key Are able read , understand provide write informed consent Informed Consent Form ( ICF ) approve Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) . Be nonsmoking male female least 18 year age date ICF sign capacity provide voluntary informed consent . Be general good health free concomititant condition treatment could interfere study conduct , influence interpretation study observations/results , place subject increase risk study . Be willing/able return require study visit follow instruction study Investigator his/her staff . Are able selfadminister eye drop clinical staff member deliver single dose investigational product ( IP ) specify study day . Have normal physical examination clinical laboratory evaluation Key Have history/presence chronic generalize systemic disease Investigator feel might increase risk subject , confound result ( ) study , preclude study treatment followup . Have current disease medical condition require medicinal therapy . Have history drug alcohol abuse last 6 month . Have positive urine screen alcohol , amphetamine , barbiturate , benzodiazepine , cocaine ( cocaine metabolite ) , cannabinoids , methadone , methamphetamine , opiates and/or phencyclidine . Are known prior positive blood screen hepatitis B surface antigen , hepatitis C antibody , human immunodeficiency virus type 1 2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>